Victoria Johnson

argenx's efgartigimod-alfa therapy was approved for seropositive generalized myasthenia gravis in 2021.

A groundbreaking study reveals that combining ixekizumab and tirzepatide significantly improves outcomes for adults with psoriatic arthritis and obesity.

This rheumatology month in review emphasizes new data and impactful approvals.

The Q4 recap for rheumatology spotlights regulatory and clinical advances across rheumatic diseases.

Johnson & Johnson plans to initiate a phase 3 study based off the positive data.

The rheumatology year in review highlights FDA approvals and pivotal data readouts.

This FDA News Month in Review provides a round-up of regulatory decisions from December 2025.

The rheumatoid arthritis year in review highlights FDA approvals, data, and advances in 2025.

The fibromyalgia year in review highlights FDA approvals, data, and advances in 2025.

The asthma year in review highlights FDA approvals, data, and advances in 2025.

A new study reveals ligdolinurad effectively lowers uric acid levels in gout patients, showcasing promising safety and tolerability results.

New data support firsekibart's efficacy over colchicine for preventing acute gout flares.

This rheumatology month in review emphasizes new data from the ACR Convergence.

A compilation of 13 trials presented as late-breaking data at ACR Convergence 2025.

The rheumatology month in review emphasizes new data presented at the 2025 ACR Convergence.

Ianalumab significantly reduces Sjögren disease activity, meeting the primary outcome in recent phase 3 trials.

Mepolizumab shows significant real-world benefits in reducing end-organ dysfunction.

Switching to an IL-17 inhibitor after TNF inhibitor failure showed no superior benefits for axial spondyloarthritis.

TENS combined with physical therapy significantly alleviates fibromyalgia pain and fatigue.

A recent exploratory analysis reveals significant kidney B-cell depletion by the recently approved drug.

Telitacicept significantly alleviates Sjögren disease symptoms over 48 weeks, outperforming placebo with a favorable safety profile in a phase 3 trial.

View slated expert interviews and 6 clinical RA, PsA, and lupus trials to watch at ACR 2025.

However, a notable higher rate of treatment-related adverse events warrants caution.

Sonelokimab meets ACR50 primary endpoint in a phase 2 trial.

Q3 2025 saw a number of exciting approvals and data on promising therapies in development.

Q3 2025 saw several new first targeted therapies for rare and more individualized indications in a number of fields.

The rheumatology month in review emphasizes new approvals and the latest comparative research.

Risankizumab shows significant and lasting improvements in psoriatic arthritis symptoms, addressing multiple disease domains and enhancing patient quality of life.

Upadacitinib reduced glucocorticoid doses and improved disease activity over 104 weeks.

Study data favored the placebo group, although differences were not clinically meaningful.